Chris Brittain of Genentech discusses FDA approval to relaunch Susvimo

Chris Brittain, vice president, Global Head of Ophthalmology Product Development at Genentech, sat with Ophthalmology Times to discuss the company's plans with Susvimo following the FDA approval for relaunch.

Video Transcript:

David Hutton:

Hi I'm David Hutton of Ophthalmology Times. Joining me today is Chris Brittain, vice president, Global Head of Ophthalmology Product Development at Genentech discussing the company's plans with Susvimo. Thanks for joining us. Tell us about what's up.

Chris Brittain:

Thanks, David. So we're really excited that Genentech is reintroducing Susvimo for people with wet age related macular degeneration. This is great news for patients with wet AMD as Susvimo offers the first alternative to regular eye injections that are the current standard of care. We're looking forward to making Susvimo available to US retinal specialists and their patients with wet AMD in the near future. Susvimo's return to the retinal community reflects our unwavering commitment to provide truly innovative retinal treatments, and lays the groundwork for future advancements. The port delivery platform, by way of an example, is currently being studied with other investigational medicines. For example, we're testing it with a biospecific drug. So in summary, we're just absolutely delighted and excited to be bringing Susvimo back to the US community.